Welcome to our dedicated page for Nanobiotix S.A. American Depositary Shares news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. American Depositary Shares stock.
Nanobiotix S.A. (Euronext: NANO / ISIN: FR0011341205) is a leading clinical-stage nanomedicine company specializing in the development of groundbreaking approaches for cancer treatment. The company's core technology, NanoXray, augments the effectiveness of radiotherapy, offering a more efficient treatment option for cancer patients. The innovative NanoXray products are designed to be compatible with existing radiotherapy treatments and aim to treat a broad spectrum of solid tumors, such as soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma.
The primary product candidate, NBTXR3, is currently undergoing evaluation for its efficacy in treating soft tissue sarcoma, head and neck cancers, prostate cancer, and liver cancers (both primary and metastases). Additionally, Nanobiotix has partnered with PharmaEngine in Taiwan to conduct trials for head and neck cancer and rectal cancer in the Asia Pacific region.
Nanobiotix has also embarked on a preclinical research program in immuno-oncology, further expanding its portfolio and potential for transformative cancer therapies. NBTXR3 works by magnifying the effects of radiotherapy within tumor cells, thereby enhancing cancer treatment without increasing the dose to surrounding healthy tissues.
Recently, Nanobiotix has been focused on validating the safety and efficacy of RT-activated NBTXR3 by moving to global registration for LA-HNSCC, accounting for the majority of its operational and financial resources. The company plans to provide an updated global development plan for NBTXR3 after further alignment with the Joint Steering Committee (JSC).
In terms of financial performance, Nanobiotix has laid out a cautious strategy, ensuring that it remains well-funded to support ongoing and future operations. Their forward-looking statements highlight the potential risks and uncertainties that could affect their business and financial performance.
For the latest updates, Nanobiotix has scheduled a conference call and webcast on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST. It continues to engage the market, providing transparency to shareholders through various media and regular updates on their progress and milestones.
To keep up with the latest news, visit www.nanobiotix.com.
Nanobiotix (NASDAQ: NBTX) announced updates at the 2021 ASCO Annual Meeting regarding its leading oncology product NBTXR3 for treating head and neck cancer and advanced cancers. The data shows NBTXR3's potential to enhance the effectiveness of radiotherapy and immunotherapy. In a phase I study, patients with locally advanced head and neck squamous cell carcinoma exhibited an 82.5% objective response rate. The company is set to launch a pivotal phase III trial for NBTXR3 in 2021. Positive long-term safety data from a soft tissue sarcoma study was also reported.
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX) announced that CEO Laurent Levy will present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 7:00 AM ET. A live webcast will be available on their website, with a replay to follow. The company, founded in 2003 and headquartered in Paris, focuses on physics-based approaches to cancer treatment. Its lead product, NBTXR3, is authorized in Europe for soft tissue sarcoma under the brand Hensify®.
Nanobiotix (NASDAQ: NBTX) announces a partnership with LianBio to develop NBTXR3, a new cancer treatment, in Greater China and other Asian markets. LianBio will handle commercial development, with Nanobiotix receiving a $20 million upfront payment and potential milestone payments totaling up to $220 million. The collaboration includes participation in a Phase III study for head and neck cancer. NBTXR3 has shown promise in treating solid tumors and has received Fast Track designation from the FDA for certain patient groups.
Nanobiotix (NASDAQ: NBTX) announces a partnership with LianBio to develop NBTXR3, an innovative radioenhancer for cancer treatment, in Greater China and other Asian markets. Nanobiotix will receive a $20 million upfront payment and potential milestone payments of up to $220 million. The agreement allows LianBio to obtain exclusive commercialization rights for NBTXR3, while Nanobiotix continues to fund its global phase III study for head and neck cancer. This strategic collaboration aims to enhance treatment options for cancer patients in the region.
Nanobiotix (NASDAQ: NBTX) reported operational progress and cash position for Q1 2021. The company has €107.1 million in cash, significantly up from €28 million in Q1 2020. Despite this, no revenue was generated in Q1 2021, a drop from €24,000 in Q1 2020 due to the end of a collaboration with PharmaEngine. Notable advancements include promising preclinical data for NBTXR3 and the initiation of a phase I trial in esophageal cancer. Collaborations with Sanofi and the retention of IP rights in the Asia-Pacific region were also highlighted.
NANOBIOTIX (NASDAQ: NBTX) announced it will present new data from its oncology pipeline at the 2021 ASCO Annual Meeting from June 4-8. Four abstracts will showcase NBTXR3, a potential first-in-class radioenhancer, across various tumor types and in combination with anti-PD-1 therapies. Key studies include an updated analysis of NBTXR3 in head and neck cancer, with plans for a global phase III trial in 2021. The company will host a virtual investor event on June 11 to discuss these results.
NANOBIOTIX (NASDAQ: NBTX) announced its annual Combined Shareholders Meeting will be held online on April 28, 2021, at 5pm CET with no physical attendance due to COVID-19 measures. Shareholders can vote via postal voting or proxy, with details available in the convene notice published in the Bulletin des Annonces Légales Obligatoires. Written questions must be submitted by April 22, 2021. The meeting format may change according to health regulations. NANOBIOTIX focuses on physics-based cancer treatment innovations and holds numerous patents in nanomedicine.
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX), a late-stage clinical biotechnology company, announced the filing of its universal registration document and annual report for the fiscal year ended December 31, 2020. These documents, which include the annual financial report and management report, are available on the company's website and the regulatory authorities' sites. Nanobiotix is pioneering physics-based approaches in oncology and has market authorization for its lead product, NBTXR3, in Europe for soft tissue sarcoma. The company is headquartered in Paris and operates subsidiaries in Spain and Germany.
Nanobiotix (NANO, NBTX) reported its fiscal year 2020 results, highlighting stable revenues of €2.5M, primarily from research tax credit and collaboration agreements. Net loss decreased to €33.6M from €50.9M in 2019. R&D expenses fell to €24.3M due to cost-control measures. The company achieved significant milestones, including FDA fast track designation for NBTXR3 in head and neck cancer and progressing towards global phase III trials. Successful IPO raised €93.5M, enhancing financial stability as they aim to advance cancer treatment solutions.
FAQ
What is the current stock price of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is the market cap of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is Nanobiotix S.A. known for?
What is NanoXray technology?
What types of cancer does NBTXR3 target?
Who is Nanobiotix partnered with in the Asia Pacific region?
What recent projects are Nanobiotix involved in?
When is the next conference call and webcast scheduled?
How does NBTXR3 enhance radiotherapy?
What is the significance of Nanobiotix’s preclinical research program?
Where can I find more information about Nanobiotix?
